After plunging 6.98 per cent to Rs 1,271 in intra-day, the scrip finally ended at Rs 1,322.50, down 3.22 per cent on BSE.
On NSE, the stock slipped 2.13 per cent to close at Rs 1,327.55.
The Medicines and Healthcare Products Regulator Agency (UKMHRA) had conducted an inspection at the company's facility at Taloja earlier last month with respect to marketing authorisation applications made by the company to the EU countries.
"The company does not anticipate any impact on its existing registered products in the EU market," it had said.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
